BeiGene reports strong 2024 results, aims for profitability in 2025

BeiGene (HKEX:6160) announced strong unaudited results for the three months ended December 31, 2024, and audited results for the year, signaling continued revenue growth and progress toward profitability. Total global revenues reached $1.1 billion for the quarter and $3.8 billion for the year, representing increases of 78% and 55%, respectively, driven by BRUKINSA and tislelizumab. Global BRUKINSA revenues increased 100% for the quarter and 105% for the year. Key pipeline programs, including sonrotoclax and BTK CDAC BGB-16673, also progressed, and six new molecular entities entered the clinic in the fourth quarter. The company expects positive GAAP operating income and operating cash flow in 2025.